|
Study | Subjects | Sample size (ITC/Con) | Baseline weight (kg) ITC vs. Con | Baseline BMI (kg/m2) ITC vs. Con | ITC dose (g/d) | Duration | Control | Diabetes duration (year) ITC vs. Con | Hypoglycemic agents | Positive indices | Negative indices |
|
Aliasgharzadeh 2015 [16] | T2DM | 52 (27/25) |
|
| 10 | 8 w | Maltodextrin | 8.50 (5.00) 5.30 (4.60) | Metformin Glibenclamide | FPG and HbA1c () | — |
Roshanravan 2017 [18] | T2DM | 59 (15/15) |
|
| 10 | 45 d | Starch powder |
| First-line preventive medications | — | FPG, insulin, HbA1c, and HOMA-IR |
Bonsu 2012 [32] | T2DM | 26 (12/14) |
|
| 10 | 12 w | Xylitol |
| NG | — | FPG and HbA1c |
Alles 1999 [33] | T2DM | 20 (20/20) | NG | NG | 15 | 20 d | Glucose | NG | Glucose-lowering medication | — | FPG |
Luo 2000 [19] | T2DM | 10 (10/10) | | | 20 | 4 w | Sucrose | | Metformin Sulfonylurea | — | Basal hepatic glucose, FPG, insulin, and HbA1c |
Guess 2015 [20] | Obesity | 39 (20/19) |
|
| 30 | 18 w | Cellulose | None | None | FPG () | Insulin and HOMA-IR |
Guess 2016 [34] | Obesity | 40 (20/20) |
|
| 30 | 2 w | Cellulose | None | None | iAUC(0-30 min) insulin () and iAUC(0-60 min) insulin () | FI, tAUC glucose/insulin, and HOMA-IR |
Rebello 2015 [35] | Obesity | 28 (14/14) |
|
| 4 | 4 w | Placebo | None | None | Blood glucose tolerance () | Insulin sensitivity, HOMA-IR, and HbA1c |
Dewulf 2013 [36] | Obesity | 30 (15/15) |
|
| 16 | 3 m | Maltodextrin | None | None | Post-OGTT glycemia () | HbA1c, FPG, insulin, post-OGTT insulinemia, and HOMA index |
Daud 2014 [37] | Obesity | 22 (12/10) |
|
| 30 | 6 w | Cellulose | None | None | — | Glucose, insulin, HOMA-IR, and HOMA % β |
de Luis 2013 [38] | Obesity | 36 (18/18) |
|
| 9.84 | 1 m | Control cookie | None | None | — | FPG, insulin, and HOMA-IR |
Parnell 2009 [39] | Obesity | 39 (21/18) |
|
| 21 | 12 w | Maltodextrin | None | None | Postprandial insulin () | Postprandial glucose and FPG |
Genta 2009 [17] | Obesity | 35 (20/15) |
|
| 10 | 4 m | Control syrup | None | None | FI and HOMA-IR () | FPG |
Tovar 2012 [40] | Obesity | 59 (30/29) |
|
| 10 | 3 m | No treatment | None | None | — | FPG |
|